- Home
- NMTC vs RVPH Comparison
NMTC vs RVPH Comparison
Compare NMTC & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMTC
- RVPH
- Stock Information
- Founded
- NMTC 2009
- RVPH 2006
- Country
- NMTC United States
- RVPH United States
- Employees
- NMTC N/A
- RVPH N/A
- Industry
- NMTC Medical/Dental Instruments
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- NMTC Health Care
- RVPH Health Care
- Exchange
- NMTC Nasdaq
- RVPH Nasdaq
- Market Cap
- NMTC 33.8M
- RVPH 32.8M
- IPO Year
- NMTC N/A
- RVPH N/A
- Fundamental
- Price
- NMTC $0.82
- RVPH $0.40
- Analyst Decision
- NMTC Strong Buy
- RVPH Strong Buy
- Analyst Count
- NMTC 1
- RVPH 5
- Target Price
- NMTC $1.45
- RVPH $9.00
- AVG Volume (30 Days)
- NMTC 185.7K
- RVPH 3.9M
- Earning Date
- NMTC 08-13-2025
- RVPH 08-13-2025
- Dividend Yield
- NMTC N/A
- RVPH N/A
- EPS Growth
- NMTC N/A
- RVPH N/A
- EPS
- NMTC N/A
- RVPH N/A
- Revenue
- NMTC $5,758,777.00
- RVPH N/A
- Revenue This Year
- NMTC $157.28
- RVPH N/A
- Revenue Next Year
- NMTC $41.79
- RVPH N/A
- P/E Ratio
- NMTC N/A
- RVPH N/A
- Revenue Growth
- NMTC 54.53
- RVPH N/A
- 52 Week Low
- NMTC $0.40
- RVPH $0.30
- 52 Week High
- NMTC $1.39
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- NMTC 61.57
- RVPH 37.92
- Support Level
- NMTC $0.69
- RVPH $0.38
- Resistance Level
- NMTC $0.77
- RVPH $0.45
- Average True Range (ATR)
- NMTC 0.04
- RVPH 0.04
- MACD
- NMTC 0.00
- RVPH 0.01
- Stochastic Oscillator
- NMTC 83.40
- RVPH 59.36
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.